Pathos AI, Bristol Myers and Tempus AI Collaborate on Drug Development Tools

Pathos AI said it entered a collaboration with Bristol Myers Squibb and Tempus AI to develop AI tools for Alzheimer’s disease and other neurological disorders. Pathos AI also raised $237 million in a Series E funding round.